ReachRxResearch
Home
Research
Sign Up
Macrophage lipid signaling drives glioblastoma invasion and represents a therapeutic vulnerability
Back to Research Hub
  1. Home
  2. Research Hub
  3. Macrophage lipid signaling drives gliobl…

Macrophage lipid signaling drives glioblastoma invasion and represents a therapeutic vulnerability

Cancer Cell·October 27Open Access
OncologyPractice changingGlioblastomaPreclinical Study (In Vivo / Ex Vivo)CSF1R InhibitorLPA Receptor AntagonistPI3K InhibitorYAP/TAZ InhibitorAdultLysophosphatidic Acid Receptor Antagonist

Summary

View source

What was studied

This study examined how tumor-associated microglia/macrophages (TAMs) promote glioblastoma (GBM) invasion through lipid-mediated paracrine signaling, using single-cell transcriptomics, spatial lipidomics, and functional perturbation in mouse models and human GBM samples.

Key findings

Invading GBM cells reprogram myeloid cells via CSF1R-PI3K signaling, triggering secretion of bioactive lipids (LPCs and LPAs); disrupting this myeloid-GBM axis reduced lipid secretion and suppressed invasion, with further constraint achieved by targeting downstream LPA receptor (LPAR) or YAP/TAZ signaling.

Study limitations

Findings are primarily preclinical (mouse models and ex vivo human samples), with no reported clinical trial data or patient survival outcomes; the context-dependency of LPAR vs. YAP/TAZ targeting is not fully characterized; sample sizes for human GBM cohorts are not specified in the abstract.

Clinical implications

The CSF1R-PI3K–lipid axis in TAMs is a potential therapeutic target to reduce GBM invasion and improve the extent of surgical resection; LPAR antagonism or YAP/TAZ inhibition may be rational add-on strategies, though clinical validation is still needed.

Caveats

  • All findings are derived from mouse models and human tumor samples; no clinical trial or patient survival data are reported, limiting direct clinical translation at this stage
  • The relative benefit of LPAR vs. YAP/TAZ targeting is described as context-dependent, and the specific determinants of that context are not yet defined
  • This paper was published in 2026; the findings are very recent and have not yet been independently replicated or validated in prospective studies

Related Questions

Explore related topics

CSF1R inhibition in glioblastoma tumor microenvironment clinical trialsLPA receptor antagonists in brain tumor invasionYAP/TAZ signaling as a therapeutic target in glioblastoma

Publication Details

Year
2026
Journal
Cancer Cell
Source
View article
Keep scrolling
More content below.
Up Next